[{"address1": "Modi\u2019in Technology Park", "address2": "2 HaMa\u2019ayan Street", "city": "Hevel Modi'in", "zip": "7177871", "country": "Israel", "phone": "972 8 642 9100", "fax": "972 8 642 9101", "website": "https://www.biolinerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.", "fullTimeEmployees": 79, "companyOfficers": [{"maxAge": 1, "name": "Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA", "age": 63, "title": "Chief Executive Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 598000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mali  Zeevi CPA, CPA", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 374000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ella  Sorani Ph.D.", "age": 55, "title": "Chief Development Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 452000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Holly W. May M.B.A.", "age": 61, "title": "President of BioLineRx USA", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 710000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Lacey", "title": "Head of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tsipi  Keren-Lehrer B.Sc., L.L.B.", "title": "Head of BD & Strategic Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Raziel  Fried", "title": "Treasurer & Budgetary Control Director", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.6565, "open": 0.6334, "dayLow": 0.6334, "dayHigh": 0.6789, "regularMarketPreviousClose": 0.6565, "regularMarketOpen": 0.6334, "regularMarketDayLow": 0.6334, "regularMarketDayHigh": 0.6789, "beta": 0.927, "forwardPE": -0.72806454, "volume": 175910, "regularMarketVolume": 175910, "averageVolume": 432470, "averageVolume10days": 602640, "averageDailyVolume10Day": 602640, "bid": 0.6591, "ask": 0.6897, "bidSize": 500, "askSize": 500, "marketCap": 54127308, "fiftyTwoWeekLow": 0.61, "fiftyTwoWeekHigh": 2.53, "priceToSalesTrailing12Months": 11.276523, "fiftyDayAverage": 1.0506, "twoHundredDayAverage": 1.43255, "currency": "USD", "enterpriseValue": 704326528, "floatShares": 989893595, "sharesOutstanding": 79939296, "sharesShort": 324649, "sharesShortPriorMonth": 183915, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0082, "heldPercentInsiders": 0.08543, "heldPercentInstitutions": 0.01437, "shortRatio": 1.74, "impliedSharesOutstanding": 75170304, "bookValue": 0.012, "priceToBook": 56.425, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -60614000, "trailingEps": -0.9, "forwardEps": -0.93, "pegRatio": 0.02, "lastSplitFactor": "1:15", "lastSplitDate": 1563148800, "enterpriseToRevenue": 146.735, "enterpriseToEbitda": -16.701, "52WeekChange": -0.39285713, "SandP52WeekChange": 0.23061275, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BLRX", "underlyingSymbol": "BLRX", "shortName": "BioLineRx Ltd.", "longName": "BioLineRx Ltd.", "firstTradeDateEpochUtc": 1311773400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e62a36f1-05bb-3c53-9aee-d33adfbdf394", "messageBoardId": "finmb_5015080", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.6771, "targetHighPrice": 21.0, "targetLowPrice": 6.5, "targetMeanPrice": 13.75, "targetMedianPrice": 13.75, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 42994000, "totalCashPerShare": 0.04, "ebitda": -42172000, "totalDebt": 11591000, "quickRatio": 1.432, "currentRatio": 1.529, "totalRevenue": 4800000, "debtToEquity": 87.658, "revenuePerShare": 0.075, "returnOnAssets": -0.383, "returnOnEquity": -1.8923, "freeCashflow": -9602375, "operatingCashflow": -22608000, "grossMargins": 0.23083, "operatingMargins": -2.4714599, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-23"}]